Evidence map›Paper›PMID 26705329›Full record

ArticleRheumatology (Oxford, England)2016

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients.

Evo Alemao, Helene Cawston, Francois Bourhis, Maiwenn Al, Maureen P M H Rutten-van Mölken, Katherine P Liao, Daniel H Solomon

Open access · bronzeAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Evo AlemaoGlobal Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA, evo.alemao@bms.com.
Helene CawstonReal World Strategy & Analytics, MAPI, Nanterre, France.
Francois BourhisReal World Strategy & Analytics, MAPI, Nanterre, France.
Maiwenn AlErasmus University Rotterdam, Institute of Medical Technology Assessment and Institute of Health Policy and Management, The Netherlands and.
Maureen P M H Rutten-van MölkenErasmus University Rotterdam, Institute of Medical Technology Assessment and Institute of Health Policy and Management, The Netherlands and.
Katherine P LiaoDivision of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
Daniel H SolomonDivision of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · USErasmus University Rotterdam · NLMapi Research Trust · FRBristol-Myers Squibb (United States) · US

Funding

Genetic Risk Factors for Coronary Artery Disease in Rheumatoid ArthritisK08AR060257 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LIAO, KATHERINE PHOENIX · 2011 to 2015
$649k
NIAMS NIH HHS K08 AR060257NIAMS NIH HHS K08AR060257
6 · The paper itself

Abstract

objectiveRA is associated with a 50-60% increase in risk of cardiovascular (CV) death. This study aimed to compare management of CV risk factors in RA and matched non-RA patients.

methodsA retrospective cohort study was conducted using UK clinical practice data. Patients presenting with an incident RA diagnosis were matched 1:4 to non-RA patients based on a propensity score for RA, entry year, CV risk category and treatment received at index date (date of RA diagnosis). Patients tested and treated for CV risk factors as well as those attaining CV risk factor management goals were evaluated in both groups.

resultsBetween 1987 and 2010, 24 859 RA patients were identified and matched to 87 304 non-RA patients. At index date, groups had similar baseline characteristics. Annual blood pressure, lipids and diabetes-related testing were similar in both groups, although CRP and ESR were higher in RA patients at diagnosis and decreased over time. RA patients prescribed antihypertensives increased from 38.2% at diagnosis to 45.7% at 5 years, from 14.0 to 20.6% for lipid-lowering treatments and from 5.1 to 6.4% for antidiabetics. Similar treatment percentages were observed in non-RA patients, although slightly lower for antihypertensives. Modest (2%) but significantly lower attainment of lipid and diabetes goals at 1 year was observed in RA patients.

conclusionThere were no differences between groups in the frequency of testing and treatment of CV risk factors. Higher CV risk in RA patients seems unlikely to be driven by differences in traditional CV risk factor management.

Indexed as

AdolescentAdultAgedAntihypertensive AgentsArthritis, RheumatoidCardiovascular DiseasesDisease ManagementDrug UtilizationFemaleHumansHypoglycemic AgentsHypolipidemic AgentsMaleMiddle AgedRetrospective StudiesRisk FactorsAntihypertensive AgentsHypoglycemic AgentsHypolipidemic AgentscardiovascularcohortdiabetesdyslipidaemiagoalhypertensionmanagementprescriptionRA

Identifiers

PMID26705329
PMCPMC4830910
OpenAlexW2244663006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.